Literature DB >> 3132059

Comparison of a computer-assisted infusion versus intermittent bolus administration of alfentanil as a supplement to nitrous oxide for lower abdominal surgery.

M E Ausems1, J Vuyk, C C Hug, D R Stanski.   

Abstract

The anesthesiologist attempts to balance the dose or concentration of an anesthetic against the intensity of noxious stimulation so as to: 1) maintain a satisfactory anesthetic state, 2) minimize side effects and toxicity of the anesthetic, and 3) allow for a rapid recovery from anesthesia. The development of infusion pumps controlled by computers programmed according to pharmacokinetic principles should facilitate the achievement of these objectives for intravenous drugs. To test this hypothesis, the authors compared anesthetic conditions achieved with a computer-controlled infusion to those produced by the traditional method of intermittent intravenous injections. In both cases, the intravenous opiate, alfentanil, was used to supplement nitrous oxide anesthesia, and the dose/dose-rate of alfentanil after the induction dose was guided by the use of precisely defined clinical signs of inadequate anesthesia. One group of ten patients received 10 mg of alfentanil and 66% N2O to induce anesthesia, and was subsequently given 1 or 2 mg iv doses of alfentanil whenever the depth of anesthesia was inadequate. A second group of ten patients had a target alfentanil concentration of 475 ng/ml of plasma established by the computer-controlled infusion, which subsequently raised or lowered the concentration by 50 or 100 ng/ml according to the presence or absence of clinical signs of inadequate anesthesia. Regular measurements of alfentanil concentrations in plasma showed that the computer-assisted infusion produced relatively stable concentrations that closely paralleled those predicted (prediction error of -64 +/- 40 ng/ml [+/- SD] in the range of 150-600 ng/ml). The traditional method of intermittent injections resulted in continuous, rapid fluctuations in alfentanil concentrations. Both methods were successful in controlling the patients' responses to noxious stimuli, but the infusion group had: 1) a lower incidence of responsiveness, 2) greater hemodynamic stability, 3) no patients requiring naloxone for satisfactory ventilation postoperatively, and 4) an incidence of side effects that tended to be lower. The previously reported alfentanil concentration versus anesthetic effect relationships were confirmed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132059     DOI: 10.1097/00000542-198806000-00004

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Target-controlled infusion systems: role in anaesthesia and analgesia.

Authors:  M C van den Nieuwenhuyzen; F H Engbers; J Vuyk; A G Burm
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Influence of age on the pharmacokinetics of alfentanil. Gender dependence.

Authors:  H J Lemmens; A G Burm; P J Hennis; M P Gladines; J G Bovill
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.

Authors:  A Van Peer; E Snoeck; M L Huang; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

4.  Anaesthetic technique does not influence postoperative bowel function: a comparison of propofol, nitrous oxide and isoflurane.

Authors:  A G Jensen; S H Kalman; P O Nyström; C Eintrei
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

Review 5.  Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia.

Authors:  H J Lemmens
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

6.  Continuous opioid infusions for neurosurgical procedures: a double-blind comparison of alfentanil and fentanyl.

Authors:  W A Mutch; K R Ringaert; F J Ewert; I W White; N Donen; R J Hudson
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.